Skip to content

MiNK Therapeutics, Inc.

INKT

CIK 0001840229

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$12.63M
−15.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.98
−2.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$10.06M
Q1 May 2026
Cash
$9.53M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
4.98M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings